MicroRNAs as immune regulators: implications for transplantation.

PubWeight™: 1.16‹?› | Rank: Top 10%

🔗 View Article (PMC 2887485)

Published in Am J Transplant on February 25, 2010

Authors

A Harris1, S M Krams, O M Martinez

Author Affiliations

1: Program in Immunology, Stanford University School of Medicine, Stanford, CA, USA.

Articles citing this

miRSystem: an integrated system for characterizing enriched functions and pathways of microRNA targets. PLoS One (2012) 1.54

Liver microRNA Profile of Induced Allograft Tolerance. Transplantation (2016) 1.42

MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors. Blood (2014) 1.32

Therapeutic hypothermia alters microRNA responses to traumatic brain injury in rats. J Cereb Blood Flow Metab (2011) 1.15

Molecular diagnostics in transplantation. Nat Rev Nephrol (2010) 1.01

MicroRNAs as biomarkers in solid organ transplantation. Am J Transplant (2012) 0.99

Allogeneic T cell responses are regulated by a specific miRNA-mRNA network. J Clin Invest (2013) 0.98

Differential expression of microRNAs during allograft rejection. Am J Transplant (2012) 0.98

miRNA profiling discriminates types of rejection and injury in human renal allografts. Transplantation (2013) 0.96

The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease. Immunol Res (2014) 0.83

MiR-152 may silence translation of CaMK II and induce spontaneous immune tolerance in mouse liver transplantation. PLoS One (2014) 0.83

Differential expression and functions of microRNAs in liver transplantation and potential use as non-invasive biomarkers. Transpl Immunol (2013) 0.83

Modulation of immune responses following solid organ transplantation by microRNA. Exp Mol Pathol (2012) 0.82

Profiling T cell activation using single-molecule fluorescence in situ hybridization and flow cytometry. J Immunol (2014) 0.80

B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. Transplant Rev (Orlando) (2010) 0.79

Hypoxia alters MicroRNA expression in rat cortical pericytes. Microrna (2013) 0.79

Association of Serum MiR-142-3p and MiR-101-3p Levels with Acute Cellular Rejection after Heart Transplantation. PLoS One (2017) 0.78

De novo-developed antibodies to donor MHC antigens lead to dysregulation of microRNAs and induction of MHC class II. J Immunol (2015) 0.76

Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs. Br J Pharmacol (2012) 0.75

Non-invasive approaches in the diagnosis of acute rejection in kidney transplant recipients, part II: omics analyses of urine and blood samples. Clin Kidney J (2016) 0.75

Differential expression of circulating miR-21, miR-142-3p and miR-155 in renal transplant recipients with impaired graft function. Int Urol Nephrol (2017) 0.75

Role of Circulating microRNAs in the Immunopathogenesis of Rejection Following Pediatric Lung Transplantation. Transplantation (2016) 0.75

Articles cited by this

MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17

Prediction of mammalian microRNA targets. Cell (2003) 53.70

Human MicroRNA targets. PLoS Biol (2004) 34.51

Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56

MicroRNAs modulate hematopoietic lineage differentiation. Science (2003) 30.05

Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res (2005) 29.17

NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A (2006) 21.58

Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol (2009) 19.99

Requirement of bic/microRNA-155 for normal immune function. Science (2007) 16.24

An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A (2004) 13.66

Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29

Regulation of the germinal center response by microRNA-155. Science (2007) 12.25

MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A (2007) 11.42

Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10

Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol (2008) 10.42

Discovering microRNAs from deep sequencing data using miRDeep. Nat Biotechnol (2008) 10.17

MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell (2007) 9.33

miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell (2007) 9.08

Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol (2007) 8.05

Short RNAs repress translation after initiation in mammalian cells. Mol Cell (2006) 6.70

Aberrant T cell differentiation in the absence of Dicer. J Exp Med (2005) 6.58

A role for Dicer in immune regulation. J Exp Med (2006) 5.81

Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell (2008) 5.53

Microarray-based, high-throughput gene expression profiling of microRNAs. Nat Methods (2004) 5.45

miRNA profiling of naïve, effector and memory CD8 T cells. PLoS One (2007) 5.43

Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J Exp Med (2008) 4.68

Approaches to microRNA discovery. Nat Genet (2006) 4.32

miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A (2007) 4.15

Dicer-dependent microRNA pathway safeguards regulatory T cell function. J Exp Med (2008) 3.70

Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe (2009) 3.59

The RNAseIII enzyme Drosha is critical in T cells for preventing lethal inflammatory disease. J Exp Med (2008) 3.45

Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol (2008) 3.14

Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. Cell Host Microbe (2008) 3.14

An optimized isolation and labeling platform for accurate microRNA expression profiling. RNA (2005) 3.12

Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet (2009) 3.09

Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol (2009) 2.51

MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci U S A (2009) 2.36

miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA (2007) 1.90

miChip: a microarray platform for expression profiling of microRNAs based on locked nucleic acid (LNA) oligonucleotide capture probes. Methods (2007) 1.10

Dissecting microRNA-mediated gene regulation and function in T-cell development. Methods Enzymol (2007) 0.85

All for one and one for all: herpesviral microRNAs close in on their prey. Cell Host Microbe (2009) 0.77

Articles by these authors

Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology (1996) 1.89

Apoptosis as a mechanism of cell death in liver allograft rejection. Transplantation (1995) 1.81

Allograft rejection after liver transplantation for autoimmune liver diseases. Liver Transpl Surg (1998) 1.53

An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation (1995) 1.13

Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol (1997) 1.12

Heterogeneity of autoreactive T cell clones specific for the E2 component of the pyruvate dehydrogenase complex in primary biliary cirrhosis. J Exp Med (1995) 1.11

Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepatology (1995) 0.99

Differential expression of microRNAs during allograft rejection. Am J Transplant (2012) 0.98

Radiolabeled annexin V imaging: diagnosis of allograft rejection in an experimental rodent model of liver transplantation. Radiology (2000) 0.97

Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. Transplant Proc (1995) 0.96

Reduction in HLA-DR, HLA-DQ and HLA-DP expression by Leu-M3+ cells from the peripheral blood of patients with thermal injury. Clin Exp Immunol (1989) 0.92

Evidence for a nonclassical pathway of graft rejection involving interleukin 5 and eosinophils. Transplantation (1993) 0.91

Molecular definitions, autoepitopes, and enzymatic activities of the mitochondrial autoantigens of primary biliary cirrhosis. Semin Liver Dis (1989) 0.90

Apoptosis and allograft rejection in the absence of CD8+ T cells. Transplantation (2001) 0.90

Resistance to Fas-mediated apoptosis in EBV-infected B cell lymphomas is due to defects in the proximal Fas signaling pathway. J Immunol (2001) 0.90

Expression of cytokines and immune mediators during chronic liver allograft rejection. Transplantation (1995) 0.89

Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis. Liver (2001) 0.88

Elevations in IFN-gamma, IL-5, and IL-10 in patients with the autoimmune disease primary biliary cirrhosis: association with autoantibodies and soluble CD30. Clin Immunol Immunopathol (1996) 0.88

Intragraft cytokine profile during human liver allograft rejection. Transplantation (1992) 0.88

Differential patterns of circulating intercellular adhesion molecule-1 (cICAM-1) and vascular cell adhesion molecule-1 (cVCAM-1) during liver allograft rejection. Transplantation (1995) 0.88

Characterization of allograft rejection in an experimental model of small intestinal transplantation. J Gastrointest Surg (1999) 0.87

Activation of the JAK/STAT pathway in Epstein Barr virus+-associated posttransplant lymphoproliferative disease: role of interferon-gamma. Am J Transplant (2009) 0.85

Viral and immunologic aspects of Epstein-Barr virus infection in pediatric liver transplant recipients. Transplantation (1995) 0.85

Acute liver allograft rejection in the rat. An analysis of the immune response. Transplantation (1995) 0.84

Altered monocyte function in uremia. Clin Immunol Immunopathol (1990) 0.84

Effect of functional overload on enzyme levels in different types of skeletal muscle. J Appl Physiol Respir Environ Exerc Physiol (1977) 0.83

CD8+ cells are not necessary for allograft rejection or the induction of apoptosis in an experimental model of small intestinal transplantation. J Immunol (1998) 0.83

Apoptosis as a mechanism of tissue injury in liver allograft rejection. Semin Liver Dis (1998) 0.83

CD30 expression identifies a functional alloreactive human T-lymphocyte subset. Transplantation (1998) 0.81

PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas. Am J Transplant (2013) 0.81

IL-2 and IL-5 gene expression in response to alloantigen in liver allograft recipients and in vitro. Transplantation (1993) 0.79

Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. Transplantation (1998) 0.79

Expression of the cytotoxic T cell mediator granzyme B during liver allograft rejection. Transpl Immunol (1995) 0.79

Interleukin-12: a possible cytotoxic T-lymphocyte differentiation factor in allograft recipients. Transplant Proc (1995) 0.78

Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder. Am J Transplant (2013) 0.78

Significance of detecting Epstein-Barr-specific sequences in the peripheral blood of asymptomatic pediatric liver transplant recipients. Liver Transpl (2000) 0.78

Application of in situ hybridization technique for quantitative assessment of ongoing symptomatic Epstein-Barr virus infection after living related liver transplantation. Clin Transplant (1998) 0.78

Cytokines are involved in the rejection of small intestine allografts. Transplant Proc (1997) 0.77

Apoptosis as a mechanism of cell death in a rat model of liver allograft rejection. Transplant Proc (1995) 0.77

Human hepatocytes produce an isoform of FAS that inhibits apoptosis. Transplantation (1998) 0.77

EBV B lymphoma cell lines from patients with post-transplant lymphoproliferative disease are resistant to TRAIL-induced apoptosis. Am J Transplant (2006) 0.77

Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts. Transplantation (1996) 0.77

Involvement of Fas-Fas ligand interactions in graft rejection. Int Rev Immunol (1999) 0.76

Acute rejection of small intestine allografts is associated with increased expression of toll-like receptors. Transplant Proc (2010) 0.75

Circulating intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in pediatric liver recipients. Transplant Proc (1995) 0.75

Long-term nonresponsiveness to a liver allograft may be cytokine mediated. Transplant Proc (1995) 0.75

Enzymatic changes in hypertrophied fast-twitch skeletal muscle. Pflugers Arch (1976) 0.75

Distinct patterns of Th2 cytokine production during immune activation in pediatric liver allograft recipients. Transplant Proc (1995) 0.75

T-cell receptor-V alpha gene use in sequential liver allograft biopsies. Transplant Proc (1993) 0.75

New immunologic insights into mechanisms of allograft rejection. Gastroenterol Clin North Am (1993) 0.75

MHC expression on human hepatocytes before and after isolation. Transplant Proc (1991) 0.75

Intragraft eosinophilia and interleukin-5 mRNA accompany liver allograft rejection. Transplant Proc (1993) 0.75

Characterization of cytokine expression in an animal model of acute liver allograft rejection. Transplant Proc (1995) 0.75

T cell receptor usage by cytotoxic T lymphocytes against autologous human melanoma. Anticancer Res (1997) 0.75

Epstein-Barr virus infection is associated with endothelial Bcl-2 expression in transplant liver allografts. Transplantation (2002) 0.75

Elevated biliary interleukin 5 as an indicator of liver allograft rejection. Transpl Immunol (1995) 0.75